Replies to post #112050 on Biotech Values

[genisi]

The first article refers to TB-403 - the anti-PlGF mAb, ThromboGenics and BioInvent partnered with Roche in June 2008. Results from phase I trial were presented in Nov. 2009 and Roche said it will conduct dose-finding study (before starting phase II, I presume), so should start phase II soon:

http://www.genengnews.com/gen-news-highlights/bioinvent-and-thrombogenics-earn-10m-as-roche-progresses-anticancer-agent/81243419/